Autoimmune Encephalitis secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis secondary prevention focuses on reducing relapse risk and recognizing recurrent disease after an initial episode. Follow-up and preventive treatment should reflect disease subtype, previous attacks, severity, and treatment risks. Long-term immunosuppression is not routinely recommended for every patient after a first presentation.[1]
Secondary Prevention
Treatment Continuity After the Acute Episode
Autoimmune encephalitis may require bridging treatment and gradual withdrawal of corticosteroids after acute therapy. The approach depends on response, adverse effects, and anticipated relapse risk; abrupt discontinuation of prescribed immunotherapy should be avoided without a clinician-directed plan.[2]
Maintenance Immunotherapy
Autoimmune encephalitis with confirmed relapses may justify maintenance immunotherapy. Selected options include rituximab, mycophenolate mofetil, or azathioprine. Drug selection and duration require specialist review of antibody subtype, attack severity, comorbidities, and tolerability. Proposed maintenance periods are empirical; a universal fixed duration is not established.[2]
Autoimmune encephalitis with persistent residual symptoms should not automatically be interpreted as active inflammation requiring additional immunosuppression. Confirm the diagnosis and assess objective evidence before escalating treatment.[1]
Recognizing Suspected Relapse
Autoimmune encephalitis relapse may reproduce earlier symptoms or present differently. New cognitive, behavioral, seizure, movement, or functional deterioration warrants reassessment. Evaluate infection, medication effects, metabolic disturbance, and seizures as alternative explanations. Antibody titers correlate imperfectly with disease activity and should not independently determine relapse or treatment escalation.[1]
Autoimmune encephalitis follow-up should include a plan for patients and caregivers to report changes and obtain timely neurological review. Persistent deficits also require rehabilitation and symptom-directed care.[2]
Associated Neoplasm Surveillance
Autoimmune encephalitis may require repeat tumor investigation after a negative initial screen or at relapse. Surveillance depends on the neuronal antibody, phenotype, age, cancer risk, and previous findings; repeated whole-body imaging is not required for every patient.[1]
For risk-specific schedules, see screening for an associated neoplasm. Tumor treatment is discussed under surgery.
Pediatric Considerations
Autoimmune encephalitis associated with N-methyl-D-aspartate receptor (NMDAR) antibodies in children usually does not require maintenance immunosuppression beyond six months, except with severe, prolonged, or relapsing disease. International consensus recommends considering more prolonged treatment after relapse. These recommendations are specific to pediatric NMDAR antibody encephalitis and should not automatically be extended to other subtypes.[3]
Treatment Safety
Autoimmune encephalitis prevention plans must balance relapse risk against immunotherapy toxicity. For rituximab, screen for hepatitis B infection, review vaccinations, and obtain baseline blood counts; previous hepatitis B infection requires specialist assessment of reactivation prevention. Monitor for infusion reactions and serious infections.[4]
Autoimmune encephalitis patients receiving prolonged corticosteroids or combined immunosuppression may need infection prophylaxis and bone protection according to their regimen and individual risk.[2][3] These measures prevent treatment complications rather than directly preventing autoimmune relapse.
Related Chapters
- Primary prevention.
- Medical therapy.
- Pediatric treatment considerations.
- Rehabilitation.
- Symptomatic and supportive therapy.
References
- ↑ 1.0 1.1 1.2 1.3 Hahn C, Budhram A, Alikhani K, et al. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.
- ↑ 2.0 2.1 2.2 2.3 Abboud H, Probasco J, Irani SR, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.
- ↑ 3.0 3.1 Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.
- ↑ Genentech. Rituxan (rituximab): prescribing information. DailyMed, United States National Library of Medicine.